Figure 1.
Figure 1. OVA expression and antibody formation to OVA. Systemic OVA expression and antibody formation to OVA after intramuscular injection of AAV-CMV-OVA into wild-type BALB/c mice (A-B) or BALB/c mice transgenic for DO11.10 TCR (C-D). (A-B) Mice received doses of 1 × 1011 vg/animal (♦) or 1 × 1012 vg/animal (▪). (C-D) Mice received doses of 1 × 1012 vg/animal (▪) or were naive controls (•). All data points represent average of 5 animals ± SD. Panels A and C show plasma levels of OVA as a function of time after vector administration; panels B and D indicate levels of IgG1 anti-OVA as a function of time after vector administration.

OVA expression and antibody formation to OVA. Systemic OVA expression and antibody formation to OVA after intramuscular injection of AAV-CMV-OVA into wild-type BALB/c mice (A-B) or BALB/c mice transgenic for DO11.10 TCR (C-D). (A-B) Mice received doses of 1 × 1011 vg/animal (♦) or 1 × 1012 vg/animal (▪). (C-D) Mice received doses of 1 × 1012 vg/animal (▪) or were naive controls (•). All data points represent average of 5 animals ± SD. Panels A and C show plasma levels of OVA as a function of time after vector administration; panels B and D indicate levels of IgG1 anti-OVA as a function of time after vector administration.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal